The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC.
Yoshihiko Tomita
Consultant or Advisory Role - Pfizer
Honoraria - Bayer; Pfizer
Research Funding - Bayer; Pfizer
Sei Naito
Honoraria - Pfizer
Naoto Sassa
Honoraria - Bayer; Pfizer
Atsushi Takahashi
Honoraria - Bayer; Pfizer
Tsunenori Kondo
Honoraria - Bayer; Pfizer
Takuya Koie
No relevant relationships to disclose
Wataru Obara
Honoraria - Bayer; Pfizer
Yasuyuki Kobayashi
No relevant relationships to disclose
Jun Teishima
No relevant relationships to disclose
Masayuki Takahashi
Honoraria - Bayer; Pfizer
Hideyasu Matsuyama
Honoraria - Bayer; Pfizer
Takeshi Ueda
Honoraria - Bayer; Pfizer
Kenya Yamaguchi
Honoraria - Pfizer
Ken Kishida
Honoraria - Bayer; Pfizer
Ryoichi Shiroki
Honoraria - Bayer; Pfizer
Takashi Saika
Honoraria - Bayer; Pfizer
Shinohara Nobuo
Consultant or Advisory Role - Bayer; Pfizer
Honoraria - Bayer; Pfizer
Mototsugu Oya
Consultant or Advisory Role - Bayer; Pfizer
Honoraria - Bayer; Pfizer
Hiro-Omi Kanayama
Consultant or Advisory Role - Bayer; Pfizer
Honoraria - Bayer; Pfizer